surmount-1 tirzepatide non-diabetic weight loss Gastrointestinal tolerability and reduction associated with in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT‐1 to ‐4 trials - Rubino - 2025 SURMOUNT-1 Trial - Cardionerds Twitter

(2025, June)

Supply unlicensed medicinal products (specials) GOV.UK guidance page

The most frequently reported side effects of tirzepatide are gastrointestinal in nature, occurring in a substantial proportion of patients during clinical trials

This action is particularly beneficial for individuals with type 2 diabetes, as it helps to improve glycemic control

The drug is now also approved for obstructive sleep apnea in adults with obesity, where it cut the apnea-hypopnea index by about half in the SURMOUNT-OSA trial

Step-by-Step: General Guidelines for Subcutaneous Injection Patients must receive training from a healthcare provider and follow specific prescription instructions